Skip to main content

Latest news

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

CTCs prognostic in limited-stage SCLC

Cancer cells

The circulating tumor cell count can identify patients with limited-stage small-cell lung cancer who are likely to have poor survival outcomes despite treatment, report researchers who have identified 15 cells per 7.5 mL as the optimal cutoff.

Whole-body MRI staging quicker and cheaper than standard pathways in NSCLC

Patient in MRI scanner

The Streamline L trial has found that in patients with newly diagnosed non-small-cell lung cancer, a staging pathway using whole-body magnetic resonance imaging has similar accuracy but a shorter time to complete staging and lower mean per-patient costs versus standard pathways.

Immunotherapy-related AEs reviewed, underlying mechanism postulated

Cancer cell

Researchers have comprehensively analyzed the incidence of adverse events in trials of PD-1 and PD-L1 inhibitors, while another team has provided insight into the potential pathophysiologic process underlying these effects.

Latest headlines

23-05-2019 | Urothelial cancer | News

Sustained nivolumab, ipilimumab activity shown in advanced urothelial cancer

Extended follow-up of patients with unresectable locally advanced or metastatic urothelial carcinoma in the CheckMate 032 trial shows sustained antitumor activity of nivolumab alone and in combination with ipilimumab.

22-05-2019 | Clinical trial | News

Waterfall plot diagrams may overestimate response rate

Waterfall plots visually overestimate the tumor response rate to agents being tested in clinical trials, US researchers warn in JAMA Network Open.

21-05-2019 | Mesothelioma | News

No benefit with nintedanib in advanced malignant pleural mesothelioma

Adding nintedanib to pemetrexed plus cisplatin does not improve progression-free survival for patients with advanced malignant pleural mesothelioma, say researchers who conducted a phase III trial on the basis of earlier positive findings.

In depth

28-02-2019 | Lung cancer | At a glance | Article

At a glance: CheckMate lung cancer trials

Here we round up the CheckMate trials evaluating the PD-1 inhibitor nivolumab in non-small-cell lung cancer and small-cell lung cancer.

Understanding the relationship between the gut microbiome and immunotherapy

Jennifer Wargo, from The University of Texas MD Anderson Cancer Center in Houston, USA, shares her insights into recent research showing an association between intestinal microbiota and response to immunotherapy (13:27).

28-01-2019 | Immunotherapy | At a glance | Article

Gut microbiota and immunotherapy response: A round-up of the trials

A round-up of the key studies – all published in Science – that have investigated the association between the gut microbiome and response to immune checkpoint inhibitors.

Image Credits